FN1 and leiomyoma: Moreover, EGCG treatment exerted anti-fibrotic effects on leiomyoma cells by altering the activation of pro-fibrotic signaling pathways (yes-associated protein 1 (YAP), β-catenin, c-Jun N-Terminal Kinase (JNK) and protein kinase B (AKT) pathways), and significantly decreasing the expression of key fibrotic proteins like fibronectin (FN1), collagen (COL1A1), plasminogen activator inhibitor-1 (PAI-1), connective tissue growth factor (CTGF), and alpha-smooth muscle actin (ACTA2) in fibroid cells [52].